Corcept Therapeutics Inc CORT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CORT is a good fit for your portfolio.
News
-
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
-
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
-
Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
-
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
-
Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
-
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call
-
Corcept Appoints Roberto Vieira as President, Oncology
-
Corcept Therapeutics Shares Slide Premarket on Loss in Teva Patent Suit
Trading Information
- Previous Close Price
- $23.00
- Day Range
- $22.57–23.44
- 52-Week Range
- $20.96–34.28
- Bid/Ask
- $21.10 / $24.15
- Market Cap
- $2.35 Bil
- Volume/Avg
- 971,180 / 1.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- 28.88
- Price/Sales
- 5.42
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 5.99%
Company Profile
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 352
- Website
- https://www.corcept.com
Comparables
Valuation
|
Metric
|
CORT
|
NBIX
|
AVIR
|
|---|---|---|---|
Price/Earnings (Normalized) | 28.88 | 26.69 | — |
Price/Book Value | 4.77 | 5.89 | 0.56 |
Price/Sales | 5.42 | 7.13 | — |
Price/Cash Flow | 22.00 | 37.20 | — |
Price/Earnings
CORT
NBIX
AVIR
Financial Strength
|
Metric
|
CORT
|
NBIX
|
AVIR
|
|---|---|---|---|
Quick Ratio | 4.05 | 2.25 | 17.86 |
Current Ratio | 4.39 | 2.45 | 18.24 |
Interest Coverage | — | 73.20 | — |
Quick Ratio
CORT
NBIX
AVIR
Profitability
|
Metric
|
CORT
|
NBIX
|
AVIR
|
|---|---|---|---|
Return on Assets (Normalized) | 25.13% | 14.51% | −15.46% |
Return on Equity (Normalized) | 30.53% | 20.57% | −16.16% |
Return on Invested Capital (Normalized) | 27.46% | 17.92% | −19.92% |
Return on Assets
CORT
NBIX
AVIR
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jxbwhclbrk | Ygjm | $553.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dkcyxpcr | Xywmvxw | $101.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Fgdjbtxz | Ndvtbk | $98.9 Bil | |
MRNA
| Moderna Inc | Ftglskqqh | Mvz | $39.7 Bil | |
ARGX
| argenx SE ADR | Gnfqccrv | Ssjzm | $21.5 Bil | |
BNTX
| BioNTech SE ADR | Xtpbdqrw | Rvr | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mvxwkwh | Bgmjvl | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xmvdqyjq | Rjvhjx | $17.2 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dcmzcksjbs | Qqzfpjv | $12.3 Bil | |
INCY
| Incyte Corp | Zykddblw | Ztfkq | $11.8 Bil |